Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n = 13,731) and Pseudomonas aeruginosa ( n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries.
No takes yet. Share an insight, caveat, or question.
Karlowsky et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: